Simponi Indications/Uses

Rheumatoid arthritis (RA): Golimumab (Simponi), by subcutaneous (SC) administration, in combination with methotrexate (MTX), is indicated for: Reducing signs and symptoms; Inducing major clinical response; Inhibiting the progression of structural damage; Improving physical function; Improving health‑related quality of life in adult patients with moderately to severely active rheumatoid arthritis. Golimumab (Simponi) can be used in patients previously treated with TNF inhibitors.
Psoriatic arthritis (PsA): Golimumab (Simponi), by SC administration, alone or in combination with MTX, is indicated for: Reducing signs and symptoms; Improving physical function; Inhibiting the progression of structural damage; Improving enthesitis; Improving psoriasis and psoriatic nail disease; Improving health‑related quality of life in adult patients with active psoriatic arthritis.
Ankylosing spondylitis (AS): Golimumab (Simponi), by SC administration, is indicated for: Reducing signs and symptoms; Improving physical function; Improving health‑related quality of life in adult patients with active ankylosing spondylitis.
Polyarticular juvenile idiopathic arthritis (pJIA): Golimumab (Simponi), by subcutaneous administration, in combination with MTX, is indicated for treatment of polyarticular juvenile idiopathic arthritis in children with a body weight of at least 40 kg, who have responded inadequately to previous therapy with MTX.
Non-radiographic axial spondyloarthritis (nr-Axial SpA): Golimumab (Simponi) by SC administration, is indicated for: Reducing signs and symptoms; Improving spinal mobility; Improving physical function; Improving health-related quality of life in adult patients with severe active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to, nonsteroidal anti-inflammatory drugs (NSAIDs).
Ulcerative colitis (UC): Golimumab (Simponi), by SC administration, is indicated for: Reducing signs and symptoms; Inducing clinical remission; Inducing mucosal healing; Improving health-related quality of life; Maintaining clinical response; Achieving long-term clinical remission; Achieving long-term mucosal healing in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.